• Economy
  • Editor’s Pick
Money Rise Today – Investing and Stock News
  • Investing
  • Stock
Editor's Pick

Abdul El-Sayed touts ‘whole a–’ medical credentials while defending sex changes for children

by September 12, 2026
written by September 12, 2026

Michigan Democratic U.S. Senate candidate Abdul El-Sayed said the government should not restrict sex changes, arguing that “whole a–” doctors like himself should be allowed to make their own determinations for patients’ treatment plans.

The remarks came during El-Sayed’s Friday rally held at Michigan State University, during which the former Detroit Health Department head responded to a student’s question about protecting sex changes. Since launching his campaign, El-Sayed has flaunted that he is a “physician” and, if elected, he would be the first doctor to serve as a Democratic senator in 50 years. However, Fox News Digital previously reported El-Sayed has never held a medical license in Michigan or New York.

“I went to a whole a– medical school, everybody I graduated with also went to whole a– medical school,” El-Sayed said. “And then… they went to whole a– residency. Right? And some of them went to whole a– fellowship. They took whole a– exams to provide whole a– healthcare.”

DEM SENATE HOPEFUL’S ‘PHYSICIAN’ CAMPAIGN PITCH UNDER FIRE AFTER LICENSE RECORDS REVEAL KEY GAPS

“They are the experts that a patient wants to see when they seek care,” El-Sayed continued. “And the decision about what healthcare is necessary ought to be held between a patient — and or their parents if they’re under the age of 18 — and their doctor. That’s it.”

The remarks come as the Trump administration has made major strides in restricting minors’ access to “sex-rejecting” procedures, which include hormone therapy and surgeries.

Earlier this week, the Justice Department announced that Mount Sinai had joined other hospitals, like Texas Children’s Hospital, the Cleveland Clinic Foundation and Connecticut Children’s Hospital, to halt sex change procedures for children after reaching an agreement with the Trump administration.

MEDICAID ENDS FUNDING FOR CHILD SEX-CHANGE PROCEDURES AS TRUMP ADMIN SLAMS ‘EXPERIMENTAL’ TREATMENTS

El-Sayed has made the promise of “Medicare-for-all” — government-run healthcare — as the major selling point of his campaign; he said that even though the government will be covering the bill, it needs to stay out of the doctor’s decisions about a patient’s treatment plan.

“I don’t think the government gets to have a say about what healthcare is provided in what circumstances and why,” El-Sayed said. “And to me, that is the standard on which we decide how we make healthcare decisions.”

THE MEDICARE FOR ALL TRADE-OFFS SOCIALISTS AREN’T TALKING ABOUT, ACCORDING TO EXPERTS

“Not what the government says you can or can’t do, but what a patient and/or their parent, if they’re under 18, and their provider to decide. That’s the most important thing,” El-Sayed continued. “And there’s a lot of disinformation about us, what we’re talking about, when we talk about reproductive rights and when we’re talking about healthcare for the trans folks. But, in the end, the place where the rubber meets the rope is in that clinical room between a patient and a provider, and that to me is the center we should engage on.”

El-Sayed argued that Republicans agree with his belief that treatment decisions should be between a patient and their doctor, pointing to the Right to Try Act, which allows terminally ill patients to try experimental drug treatments that aren’t yet approved by the Food and Drug Administration after they have exhausted all other treatment options.

“Because conservatives fought for a very long time for this legislation called ‘Right to Try’ legislation, which is the idea that the government couldn’t tell you [that] you couldn’t have a certain medication,” El-Sayed said.

TRUMP ADMINISTRATION PROBE COULD UPEND WIDELY USED TRANSGENDER YOUTH TREATMENT GUIDELINES

“So they agree that the decision about healthcare ought to be between the person and their provider. That’s it. So let’s use that standard, and keep to that standard, and make sure the government doesn’t have the ability to tell you what you can or cannot do with your own life,” El-Sayed said.

However, the research on the efficacy of treating individuals with gender dysphoria by allowing them to change sexes with “cross-sex” hormones and puberty blockers is limited.

The World Professional Association for Transgender Health, whose guidelines are used by leading medical associations like the American Academy of Peditatrics, is currently facing a lawsuit from the Federal Trade Commission stemming from allegations that its guidelines misled parents about the “medical consensus and medical necessity, as well as the safety and effectiveness” of sex change procedures.

The FTC has accused WPATH of failing to disclose the side effects associated with some procedures, such as patients experiencing incontinence, erectile pain, mood disturbances, pelvic pain and vaginal pain stemming from “cross-sex” hormones.

Meanwhile, countries that have socialized medicine have put restrictions in place for minors seeking sex changes. In England, the National Health Service put a pause on “cross-sex” hormones for 16- and 17-year-olds in March after finding research was “really weak” to support it.

The country already had a ban in place restricting children under 16 years old from taking sex-change hormones.

El-Sayed campaign spokesperson Roxie Richner said the Senate candidate has impeccable medical credentials.

“Dr. El-Sayed earned a medical doctorate from Columbia University and a doctorate in public health from Oxford University,” she said. “That’s two doctorates—he has earned the right to be called “doctor” twice over. He has spent his career improving healthcare for Michiganders through innovative public health programs, including the elimination of millions of dollars in medical debt, increased access to Narcan, and the creation of a state-of-the-art air quality monitoring network.”

This post appeared first on https://www.foxnews.com

0 comment
0
FacebookTwitterPinterestEmail

previous post
Dem handlers lash out when cameraman confronts their boss about debate: ‘No pictures’
next post
How will private credit and equity stocks react to Fed rate hikes?

related articles

State’s largest mosque leader’s deportation fight takes dramatic...

October 1, 2026

Trump handing 1 million Americans Obamacare refund checks...

October 1, 2026

Iranian negotiators kicked out of US as talks...

October 1, 2026

10 Democrat-held House seats Republicans could flip to...

October 1, 2026

Trump’s new high-tech government hub holds some bizarre...

October 1, 2026

FAA breaks controller hiring record after chief warned...

October 1, 2026

Biden-era federal prosecutor hit with criminal investigation referral...

October 1, 2026

Teen’s tragic killing by illegal immigrant becomes flashpoint...

October 1, 2026

Election crime arrests keep piling up as Dems...

October 1, 2026

States leading nation on the biggest education battles...

October 1, 2026
Enter Your Information Below To Receive Free Trading Ideas, Latest News, And Articles.


Your information is secure and your privacy is protected. By opting in you agree to receive emails from us. Remember that you can opt-out any time, we hate spam too!

Latest News

  • Why Tesla stock is crashing around 5% today

    June 9, 2026
  • Nasdaq futures surge 190 points: 5 things to know before Wall Street opens

    July 9, 2026
  • CoreWeave and Nebius stocks in a bear market as AI bubble risk persists

    September 29, 2026
  • Raucous primary season reaches final act in deep-blue stronghold, kickstarting sprint to November

    September 15, 2026
  • Why Nvidia stock is lagging the broader chip rally on Monday

    July 6, 2026

Popular Posts

  • 1

    CoreWeave stock jumps 10% as analysts see major backlog upside

    June 16, 2026
  • 2

    Intel, AMD stocks slide again in aftermath of Broadcom’s weak outlook

    June 5, 2026
  • 3

    Dow tumbles 680 points as chip rout sends Nasdaq to biggest drop since 2025

    June 5, 2026
  • 4

    Wedbush makes a strong case for buying the dip in Planet Labs stock

    June 5, 2026
  • 5

    Wedbush makes a strong case for buying the dip in Planet Labs stock

    June 5, 2026

Categories

  • Editor's Pick (707)
  • Investing (1,641)
  • Stock (90)

Latest Posts

  • Top 5 FTSE 100 shares to watch in July: IAG, Lloyds, Rolls-Royce, Sage, NatWest

    July 1, 2026
  • Hang Seng Index: Top 3 reasons Hong Kong stocks are falling today

    August 31, 2026
  • Omar’s GOP challenger comes out firing with vow to clean up ‘mess’ in deep blue district: ‘People are fed up’

    August 18, 2026

Recent Posts

  • DraftKings stock jumps 11% as prediction markets volume surges

    June 9, 2026
  • Accenture stock plunges as Wall Street cuts targets

    June 22, 2026
  • Russia exposes NATO weapons gap as top commander warns ‘the math is not in favor of the West’

    July 28, 2026

Editor’s Pick

  • Nikkei’s record quarter leaves Asian markets asking if AI trade has run too far

    June 30, 2026
  • Alphabet stock falls 3% as Meta’s Muse AI raises competition

    September 23, 2026
  • Republican cavalry arrives for Ken Paxton as big-bucks Texas offensive opens cash floodgates

    September 11, 2026
  • About us
  • Contacts
  • Privacy Policy
  • Terms & Conditions

Disclaimer: moneyrisetoday.com, its managers, its employees, and assigns (collectively “The Company”) do not make any guarantee or warranty about what is advertised above. Information provided by this website is for research purposes only and should not be considered as personalized financial advice. The Company is not affiliated with, nor does it receive compensation from, any specific security. The Company is not registered or licensed by any governing body in any jurisdiction to give investing advice or provide investment recommendation. Any investments recommended here should be taken into consideration only after consulting with your investment advisor and after reviewing the prospectus or financial statements of the company.

Copyright © 2025 moneyrisetoday.com | All Rights Reserved

Money Rise Today – Investing and Stock News
  • Economy
  • Editor’s Pick
Money Rise Today – Investing and Stock News
  • Investing
  • Stock